Yat Sun Or
2013
In 2013, Yat Sun Or earned a total compensation of $992.8K as Senior Vice President, Research & Development and Chief Scientific Officer at Enanta Pharmaceuticals, a 64% increase compared to previous year.
Compensation breakdown
| Bonus | $143,174 |
|---|---|
| Option Awards | $501,973 |
| Salary | $343,255 |
| Other | $4,439 |
| Total | $992,841 |
Or received $502K in option awards, accounting for 51% of the total pay in 2013.
Or also received $143.2K in bonus, $343.3K in salary and $4.4K in other compensation.
Rankings
In 2013, Yat Sun Or's compensation ranked 6,646th out of 12,286 executives tracked by ExecPay. In other words, Or earned more than 45.9% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 6,646 out of 12,286 | 46th |
Division Manufacturing | 2,341 out of 4,612 | 49th |
Major group Chemicals And Allied Products | 695 out of 1,462 | 53rd |
Industry group Drugs | 507 out of 1,156 | 56th |
Industry Pharmaceutical Preparations | 402 out of 890 | 55th |
Source: SEC filing on January 13, 2016.
Or's colleagues
We found two more compensation records of executives who worked with Yat Sun Or at Enanta Pharmaceuticals in 2013.
News
Enanta Pharmaceuticals CEO Jay Luly's 2022 pay jumps 37% to $7.3M
January 20, 2023
Enanta Pharmaceuticals CEO Jay Luly's 2021 pay rises 2% to $5.3M
January 21, 2022
Enanta Pharmaceuticals CEO Jay Luly's 2020 pay rises 16% to $5.2M
January 21, 2021
Enanta Pharmaceuticals CEO Jay Luly's 2019 pay slips 1% to $4.5M
January 17, 2020
Enanta Pharmaceuticals CEO Jay Luly's 2018 pay rises 5% to $4.5M
January 18, 2019